Skip to main content

21.04.2024 | Case Report

A case of insulinoma misidentified as schizophrenia due to its manifestation in neuropsychiatric symptoms

verfasst von: Tomoyuki Haba, Kengo Yamakawa, Sayako Ozeki, Akira Sumida, Takehiro Kato, Eiji Kuroda, Takako Maruyama, Takaaki Murakami, Daisuke Yabe

Erschienen in: Diabetology International

Einloggen, um Zugang zu erhalten

Abstract

Insulinomas can present with neuroglycopenic symptoms suggesting neuropsychiatric disorders, delaying diagnosis and treatment. We recently treated a 65-year-old woman with insulinoma who was misdiagnosed at her nearby psychiatric clinic as having schizophrenia because of personality changes and memory impairment; she was treated with brexpiprazole, which was discontinued due to persistence of the symptoms. Despite her relatively low casual plasma glucose (70 mg/dL), the physician at the psychiatric clinic did not investigate the possibility of hypoglycemia, partly because her HbA1c level (5.2%) was within normal range. After skipping lunch one day, she was found by her family to be unable to communicate properly. She was transported to the emergency room of our hospital, where intermittently scanning continuous glucose monitoring (isCGM) use permitted detection of the hypoglycemia and led to a diagnosis of insulinoma and successful resection. A 72-h fasting test established hyperinsulinemic hypoglycemia. Contrast-enhanced computed-tomography and endoscopic ultrasonography together with selective arterial calcium stimulation test revealed an insulin-secreting tumor in the tail of the pancreas. Surgical resection of the tumor corrected her glucose and insulin levels as well as eliminated the insulinoma neuropsychiatric symptoms. Pathological examination showed that the tumor was positive for chromogranin A, synaptophysin and insulin. It is, therefore, important for physicians to be aware that insulinomas can manifest as neuroglycopenic symptoms and to consider the possibility of hypoglycemia by careful medical interview and isCGM, especially when patients suspected of psychiatric disorders do not show the expected response to antipsychotic drugs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41:371–403.CrossRefPubMedPubMedCentral Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41:371–403.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Masui T, Ito T, Komoto I, et al. Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan. Int J Clin Oncol. 2022;27:840–9.CrossRefPubMedPubMedCentral Masui T, Ito T, Komoto I, et al. Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan. Int J Clin Oncol. 2022;27:840–9.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30:3–17.CrossRefPubMed de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30:3–17.CrossRefPubMed
5.
Zurück zum Zitat Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67–74.PubMed Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67–74.PubMed
6.
Zurück zum Zitat Ding Y, Wang S, Liu J, Yang Y, Liu Z, et al. Neuropsychiatric profiles of patients with insulinomas. Eur Neurol. 2010;63:48–51.CrossRefPubMed Ding Y, Wang S, Liu J, Yang Y, Liu Z, et al. Neuropsychiatric profiles of patients with insulinomas. Eur Neurol. 2010;63:48–51.CrossRefPubMed
7.
Zurück zum Zitat Murakami T, Yamashita T, Yabe D, et al. Insulinoma with a history of epilepsy: still a possible misleading factor in the early diagnosis of insulinoma. Intern Med. 2017;56:3199–204.CrossRefPubMedPubMedCentral Murakami T, Yamashita T, Yabe D, et al. Insulinoma with a history of epilepsy: still a possible misleading factor in the early diagnosis of insulinoma. Intern Med. 2017;56:3199–204.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol. 2018;68:912–8.CrossRef Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol. 2018;68:912–8.CrossRef
11.
Zurück zum Zitat Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106:307–10.CrossRefPubMed Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106:307–10.CrossRefPubMed
12.
Zurück zum Zitat Imamura M, Nakamoto Y, Uose S, Komoto I, Awane M, et al. Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015;22:602–9.CrossRefPubMed Imamura M, Nakamoto Y, Uose S, Komoto I, Awane M, et al. Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015;22:602–9.CrossRefPubMed
13.
Zurück zum Zitat Dai H, Chen H, Hong X, Han X, Xu Q, et al. Early detection of cognitive impairment in patients with insulinoma. Endocrine. 2019;65:524–30.CrossRefPubMed Dai H, Chen H, Hong X, Han X, Xu Q, et al. Early detection of cognitive impairment in patients with insulinoma. Endocrine. 2019;65:524–30.CrossRefPubMed
14.
Zurück zum Zitat Moser O, Eckstein ML, McCarthy O, Deere R, Pitt J, et al. Performance of the freestyle libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: a secondary outcome analysis of a randomized crossover trial. Diabetes Obes Metab. 2019;21:2505–12.CrossRefPubMedPubMedCentral Moser O, Eckstein ML, McCarthy O, Deere R, Pitt J, et al. Performance of the freestyle libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: a secondary outcome analysis of a randomized crossover trial. Diabetes Obes Metab. 2019;21:2505–12.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14:238.CrossRefPubMed Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14:238.CrossRefPubMed
16.
Zurück zum Zitat Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin. Nature. 1995;374:542–6.CrossRefPubMed Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin. Nature. 1995;374:542–6.CrossRefPubMed
17.
Zurück zum Zitat Orthen-Gambill N, Salomon M. Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved? Pharmacol Biochem Behav. 1990;36:837–41.CrossRefPubMed Orthen-Gambill N, Salomon M. Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved? Pharmacol Biochem Behav. 1990;36:837–41.CrossRefPubMed
18.
Zurück zum Zitat Weston-Green K, Huang XF, Lian J, et al. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol. 2012;22:364–73.CrossRefPubMed Weston-Green K, Huang XF, Lian J, et al. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol. 2012;22:364–73.CrossRefPubMed
19.
Zurück zum Zitat Yamamoto N, Oh E, Nishiyama K, Yoshida M, Saeki A, et al. Case of insulinoma manifesting as hyperinsulinemia after discontinuing quetiapine in an elderly patient with delirium. Geriatr Gerontol Int. 2017;17:849–51.CrossRefPubMed Yamamoto N, Oh E, Nishiyama K, Yoshida M, Saeki A, et al. Case of insulinoma manifesting as hyperinsulinemia after discontinuing quetiapine in an elderly patient with delirium. Geriatr Gerontol Int. 2017;17:849–51.CrossRefPubMed
20.
Zurück zum Zitat Suzuki M, Niidome K, Maeda K, Kikuchi T, Usami T, et al. Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI Tablets 1mg, 2mg). Nihon Yakurigaku Zasshi. 2019;154:275–87.CrossRefPubMed Suzuki M, Niidome K, Maeda K, Kikuchi T, Usami T, et al. Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI Tablets 1mg, 2mg). Nihon Yakurigaku Zasshi. 2019;154:275–87.CrossRefPubMed
Metadaten
Titel
A case of insulinoma misidentified as schizophrenia due to its manifestation in neuropsychiatric symptoms
verfasst von
Tomoyuki Haba
Kengo Yamakawa
Sayako Ozeki
Akira Sumida
Takehiro Kato
Eiji Kuroda
Takako Maruyama
Takaaki Murakami
Daisuke Yabe
Publikationsdatum
21.04.2024
Verlag
Springer Nature Singapore
Erschienen in
Diabetology International
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00722-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.